Category Archives: Healthcare Technology

Google Cloud Announces Generative AI Advancements

for Healthcare, Life Science Organizations

ORLANDO, FL, Mar 13, 2024 – At HIMSS24, Google Cloud announced several new solutions to help healthcare and life sciences organizations enable interoperability, build a better data foundation for their businesses, and deploy generative AI (gen AI) tools to improve patient outcomes.

Vertex AI Search: smarter search for healthcare data

Healthcare administrative costs were up by 30% in 2022, to reach $60 billion annually (CAQH), physician burnout increased to 53% in 2022 (Medscape), and there is a shortage of more than 13 million nurses in the world (World Health Organization, 2020). This presents a clear opportunity for healthcare providers, payers, electronic health records companies, and life science companies to build gen AI solutions that empower healthcare workers and other employees to work more efficiently and effectively.

Launched today, Google Cloud’s Vertex AI Search for Healthcare helps developers build better assistive technology for clinicians and other health system workers to alleviate administrative burden. Specifically, it enables medically-tuned, gen AI search on a broad spectrum of data, including FHIR data and clinical notes. These search and question-answering capabilities now integrate with MedLMHealthcare Data Engine (HDE) and Cloud Healthcare FHIR APIs, making it easier for healthcare and life science organizations to build the data analytics and AI solutions needed for next era health systems.

Key Vertex AI Search for Healthcare features include:

  • Medically-tuned search: By enabling medically-tuned search on electronic health record (EHR) data, scanned documents, and other clinical data, healthcare applications can now surface the most relevant information to clinicians, and others engaged in the decision making and processing, without the need to click through hundreds of pages of notes or toggle between different screens and applications.
  • Configurable cloud APIs: Healthcare application developers can integrate the medically-tuned search directly into the clinician workflow tools using configurable cloud APIs.
  • Question-answering: Clinicians can now use the service to answer questions such as “Does the patient have a history of cancer?” which typically involves not only an understanding of medical terminology related to cancers but also understanding the nuances of language in medical notes and scanned documents.
  • Factuality: Because the results are grounded in the healthcare organizations’ real data, Vertex AI Search for Healthcare can also cite and link to the specific data points that generated the answers, providing transparency to users, increasing confidence in the responses, and helping reduce the risks of hallucinations or inaccurate responses.
  • Data platform integration: Gen AI and search applications require  high-quality data to ensure that the outputs of gen AI are useful. HDE provides automated tooling and components to build a unified high quality patient data platform quickly and easily. The out-of-the-box integration of Vertex AI Search with HDE enables search and summarization use cases without the need for custom integrations.
  • Deeper medical understanding: While MedLM tools are expert in complex medical topics, Vertex AI Search for Healthcare delivers medically-tuned search capabilities grounded in the patient record. When combined, healthcare organizations can find the most relevant answers to complex medical questions both from MedLM, as well as within the patient’s medical record. Select customers will have early access to Vertex AI Search for healthcare and life science integration with MedLM.

“Not all generative AI is created equal, and in healthcare, the stakes are particularly high,” said Aashima Gupta, global director for Healthcare Strategy & Solutions, Google Cloud. “Healthcare organizations require enterprise-grade gen AI solutions, grounded in real data. Vertex AI Search for Healthcare is already making a difference for healthcare organizations by helping ensure clinicians have the right information and insights at the right time to inform decisions and improve the overall quality of patient care.”

“At Highmark Health, we are constantly seeking ways to harness the power of data and technology to transform the healthcare ecosystem,” said Richard Clarke, chief data and analytics officer, Highmark Health. “Google Cloud’s Vertex AI Search integration with Healthcare Data Engine will enable us to provide even more personalized and proactive care to our members.”

“MEDITECH is dedicated to providing healthcare organizations with innovative tools to improve patient outcomes and streamline clinician experiences,” said MEDITECH Executive Vice President and Chief Operating Officer Helen Waters. “The ability to quickly locate information within EHRs is a well-documented problem today. MEDITECH’s vision to embed search within the Expanse workflows allows us to leverage Google Clould’s AI capabilities to ease this burden. We will continue to empower clinicians with cutting edge decision making tools and enable clinician efficiency.”

Healthcare Data Engine: healthcare data platform for the AI era

To help healthcare organizations around the world build an interoperable high quality data platform, the foundation to take advantage of gen AI, Google Cloud today announced a new consumption-priced managed service of Healthcare Data Engine (HDE), and expanded availability internationally with new features. Key updates include:

  • Simplified management, and streamlined pricing: Customers can now deploy HDE as a consumption priced, pay-as-you-go, managed service, which opens up the product to more healthcare organizations, helping them to deploy, build, and manage a near real-time healthcare data platform in the cloud.
  • Global Availability: HDE will expand beyond North America, and roll out globally to most cloud regions in Europe and in the Asia Pacific.
  • Low-code graphical data mapping IDE: By introducing HDE Data Mapper, a new low-code graphical integrated development environment (IDE), purpose-built by Google Research for healthcare, customers can easily transform their data to build high quality longitudinal patient records in FHIR format to power gen AI applications.
  • Foundation for AI and analytics solutions: By integrating HDE with Vertex AI Search for Healthcare, clinicians can look across multiple systems and formats in one search, saving valuable time that can instead be focused on patient engagement and improving the overall patient experience. Integration with MedLM will allow customers to answer complex questions grounded in the patient’s data.

“At HCA Healthcare, we’re focused on integrating technology into solutions that will empower our clinicians to perform at the top of their license and deliver exceptional patient care,” said Michael J. Schlosser, MD, MBA, FAANS, SVP, Care Transformation and Innovation, HCA Healthcare. “Google Cloud understands our commitment. Through our partnership and by deploying its Healthcare Data Engine, HCA Healthcare has the ability to harmonize data from disparate sources into a comprehensive longitudinal patient record, which is fundamental to our advanced analytics and Responsible AI initiatives.”

“Oscar is focused on reorienting the healthcare system around the consumer,” said Mario Schlosser, co-founder and chief technology officer of Oscar Health. “Our end-to-end tech stack enables us to capture the emerging opportunities of new technologies – from machine learning to generative AI – to deliver seamless experiences for members. We continue to partner with forward-looking companies like Google Cloud to accelerate our efforts and drive the change we want to see in healthcare.”

“Becoming the world’s most trusted wellbeing company is a complex journey, and one of the most critical foundational elements is a strong data strategy,” said Steve Fast, CIO, TELUS Health. “Google Cloud’s Healthcare Data Engine, search and gen AI capabilities combined with our unmatched range of services and tools to support the total health and wellbeing of our global population, will help us streamline workflows at scale, unlock deeper insights from healthcare data, and ultimately drive better health outcomes for the nearly 70 million lives we serve worldwide.”

MedLM and more: Google Research innovations coming to Google Cloud customers

Finally, MedLM, a family of foundation models fine-tuned for healthcare industry use cases, will add two new capabilities for Google Cloud customers to explore and test. First, MedLM for Chest X-ray can help with classification of chest x-rays for operational, screening, and diagnostics use cases. It is a domain-specialized model, launched as an application programming interface (API) that converts chest x-ray images into embeddings. App developers and data scientists can use those embeddings along with ground truth labels to train a simple classification model in Vertex AI.

The second new capability is a task-specific API called Condition Summary that aims to provide a chronological list of patient conditions, along with AI-generated briefs about each condition, with citations from original text.

In the coming months, Google Cloud is planning to bring additional functionality to the MedLM suite to offer even more capabilities.

Google Cloud’s customers retain control over their data. In healthcare settings, access and use of patient data is protected through the implementation of Google Cloud’s reliable infrastructure and secure data storage that support HIPAA compliance, along with each customer’s security, privacy controls, and processes.

About Google Cloud

Google Cloud is the new way to the cloud, providing AI, infrastructure, developer, data, security, and collaboration tools built for today and tomorrow. Google Cloud offers a powerful, fully integrated and optimized AI stack with its own planet-scale infrastructure, custom-built chips, generative AI models and development platform, as well as AI-powered applications, to help organizations transform. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.

For more information, visit Google Cloud website.

OrthoVentions Invests in MotioOV

to Develop 3D Printed Implant, Instruments

ATLANTA, GA, Mar 12, 2024 – OrthoVentions LLC announced its investment in MotioOV, an early-stage company created in partnership with the Hospital for Special Surgery (HSS). MotioOV is developing a novel 3D printed implant and custom instruments to address stiffness and pain associated with arthritis of the first metatarsophalangeal (MTP) joint.

Under the terms of the investment, the company will be funded to complete product development and an initial commercial launch targeting the unmet clinical need of providing a functional MTP joint implant that reduces pain and preserves motion rather than the sub-optimal treatment of joint fusion. The solution under development will consist of various implant sizes and single-use instruments customized to complete total joint arthroplasty. Complaints of arthritic toe pain account for 20-30 percent of all patient visits to foot and ankle surgeon’s practice.

“MotioOV is based on the fundamental understanding of the anatomy and associated forces of the MTP joint in an arthritic joint to invoke the design of an implant that minimizes insult to the bone and surrounding soft tissues while promoting stability,” said Dr Holly Johnson, co-founder of MotioOV and an orthopedic foot and ankle surgeon at HSS. Dr. Constantine Demetracopoulos, an orthopedic foot and ankle surgeon at HSS and Co-Founder of MotioOV added, “We have taken a comprehensive approach combining image-driven design, additive manufacturing to optimize bone in-growth and procedure-specific instruments to deliver an efficient and reproducible surgical plan.”

Jagi Gill, founder and managing director of OrthoVentions, said, “The partnership with Doctors Johnson and Demetracopoulos brings best-in-class surgical experience in fore-foot and total joint arthroplasty to lead the design of our complete solution of implant and instrumentation leveraging the expertise of our product development partners. Arthritis of the MTP joint is a growing clinical burden driven by the aging population with no viable motion preserving option.”

About OrthoVentions

OrthoVentions LLC is a dedicated healthcare fund collaborating with the Hospital for Special Surgery to identify and develop novel technologies developed by their premiere musculoskeletal surgeons. The principals at OrthoVentions bring a strong track record as founders and operators of medical technologies companies with a rich experience in developing and commercializing compelling healthcare solutions.

For more information, visit www.orthoventions.com.

Medidata, Sanofi Vaccines Extend Collaboration

Singapore, Mar 1, 2024 – Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, and Sanofi Vaccines, announced a collaboration to harness Medidata eCOA to deploy in vaccine studies. This builds on Medidata and Sanofi’s longstanding, successful experience using Medidata Rave EDC (electronic data capture).

The collaboration will use an eDiary function within eCOA to create an eDiary library specific to Sanofi’s vaccines. This library will accelerate future study set-up times, improve efficiency, and increase data quality, while ensuring patients have access to eDiaries that are easy to use.

Sanofi has chosen to adopt eCOA’s capabilities in its vaccine studies, optimizing the patient clinical journey by reducing on-site monitoring and allowing patients to input data in real time from any location. Pilots of eCOA were performed in six vaccine studies and demonstrated high levels of patient compliance, providing highly reliable data. As a result, the collaboration has since moved out of the pilot phase, with eCOA being deployed across a pipeline of Sanofi’s vaccine clinical trials.

“Expanding our collaboration with Medidata will enable us to improve our clinical development processes as we seek to deliver breakthrough vaccines to patients,” said the global head of clinical data management at Sanofi Vaccines. “Through a bespoke eDiary library, we can optimize eDiary set-up and improve data quality in current trials, while moving deeper into the digitalization era within the pharma industry.”

Anthony Costello, chief executive officer, Medidata Patient Cloud, said, “At Medidata, we put the patient at the core of all of our work, and collaborating with Sanofi, who share this ethos, helps improve patient experience, the monitoring of patients in current studies, and accelerate study timelines and efficiencies in future studies.”

Medidata eCOA is a full-service offering revolutionizing the way sponsors, contract research organizations (CROs), and sites collect data from patients, physicians, and caregivers. Built as part of the unified Medidata Platform, eCOA reduces study build times by up to 50% and provides a comprehensive view of patient data, while providing patients with flexibility and choice in how they engage in trial activities.

Sanofi has worked with Medidata for over a decade, leveraging Medidata’s solutions across the organization, including vaccine studies, to securely and efficiently capture and manage data.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 32,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC.

For more information, visit www.medidata.com.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE company, is a catalyst for human progress. They provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, their customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries.

For more information, visit www.3ds.com.

3D Systems Unveils Monolithic Denture Product Line

ROCK HILL, SC, Feb 22, 2024 – 3D Systems introduced a first-to-market solution for jetted, monolithic (one-piece) dentures that utilizes multiple materials to deliver a durable, long-wear, aesthetically beautiful prosthetic to the patient. This is enabled by the formulation of bespoke materials for both teeth and gums. These unique materials deliver the desired combination of aesthetics, wear- and stain-resistance in the teeth, with exceptional break resistance (toughness and strength) in the gums. This combination results in a denture product that is superior to all other currently available, monolithic, jetted denture solutions. When these materials are used as part of 3D Systems’ complete workflow solution comprising materials, jetted 3D printing technology, software, and services, high-volume dental laboratories can more efficiently deliver dentures with improved performance and aesthetics, resulting in a superior patient experience.

3D Systems’ materials scientists developed NextDent Jet Denture Teeth and NextDent Jet Denture Base — the former uniquely formulated to mimic tooth rigidity and aesthetics, and the latter to absorb impact. When these materials are used as part of the company’s monolithic jetted denture solution, dental labs are able to produce dentures with exceptional performance, including high break resistance, a particularly important customer need. Additionally, the speed of 3D Systems’ jetting technology combined with monolithic denture printing accelerates total production rates in order to significantly reduce time to completion resulting in expedited delivery to the prosthodontist and patient.

In recent months 3D Systems previewed this solution to select customers including Glidewell, the world’s largest producer of restorative dental devices. Stephenie Goddard, CEO, Glidewell shared, “Glidewell prides itself on being on the forefront of technology, and continually bringing innovation to the dental community. Therefore, we need to collaborate with solution providers who share our vision for the power of transformative innovation. As a long-time 3D Systems customer, Glidewell continues to be impressed by the company’s leadership in digital dentistry. The capabilities presented by the new jetted denture solution are unmatched in the industry. The combination of 3D Systems’ high-speed printing technology and its unique materials deliver dentures with superior durability and aesthetics. I’m looking forward to our implementation of this solution later this year, and the benefits it will deliver not only for our business but for our customers and their patients.”

“With each innovation to our digital dentistry portfolio, 3D Systems has been able to help our customers transform the devices they deliver, and how clinicians deliver patient care,” said Chuck Stapleton, vice president & general manager, dental, 3D Systems. “As we announce our jetted denture solution today, I’m proud that we are once again delivering a truly unique offering to the market. We’ve combined innovation in materials and 3D printing, with software, post-processing, and applications expertise into our monolithic jetted denture solution, designed for high-volume production with unparalleled accuracy, repeatability, and lower total cost of operation. I look forward to seeing this solution change the trajectory of denture production, not only over the coming months but in the years to follow.”

The company anticipates 510(k) clearance from the United States Food & Drug Administration (FDA) for its solution in the second half of 2024.

The adoption of 3D printing to produce prosthodontics continues to accelerate, driven by benefits to both manufacturers and patients alike. According to 360 Research Reports, the global 3D Printed Dentures market size was estimated to be more than $1 billion in 2021 and is forecast to reach more than $2 billion by 2028. With 3D Systems’ digital dentistry solutions including its solution for the production of monolithic dentures, dental laboratories and clinics are able to produce dental devices at dramatically increased speed, while reducing material waste and capital equipment expenditures. Patients also experience significant benefits, through reductions in the time it takes to receive their prosthodontics, as well as the number of required office visits.

3D Systems will showcase its new monolithic denture product line along with the breadth of applications addressed by its digital dentistry solution portfolio at LMT Lab Day, to be held February 22-24, 2024 at the Hyatt Regency Chicago (Illinois). Attendees are invited to visit the company’s booth (A-43, B-42, East Exhibit Hall) to learn more about how 3D Systems’ portfolio of entry-level dental 3D printers, mid- and large-platform 3D printers, rapidly scalable workflows and growing range of validated NextDent materials can help expand labs and clinics. Additionally, the company will highlight how it has validated the NextDent materials portfolio to perform across a wide selection of the industry’s most trusted 3D printers. Attendees are also invited to participate in 3D Systems’ seminars to be held in the Comiskey Room, West Tower, Bronze Level. For more information, please visit the company’s website.

About 3D Systems 

More than 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defense, automotive, and durable goods.

More information on the company is available at www.3dsystems.com.

Cadence Partners with Antiviral Discovery Consortium

SANTA FE, NM, Dec 8, 2023 – Cadence Molecular Sciences (OpenEye), a business unit of Cadence Design Systems, will provide OpenEye’s molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in support of an innovative effort to rapidly develop antivirals to prevent future pandemics.

John D. Chodera, PhD, a lab head at the Memorial Sloan Kettering Cancer Center (MSKCC), directs the researchers and software scientists building the computational chemistry infrastructure to support ASAP.

“Dr. Chodera and the ASAP scientists working with him will have access to OpenEye tools to help support the ASAP Discovery Consortium and antiviral drug research,” said Anthony Nicholls, PhD, corporate vice president, OpenEye, Cadence Molecular Sciences. “OpenEye’s software will aid in advancing therapeutics for under-researched diseases and to prepare for pandemics.”

OpenEye’s Applications, Toolkits and Orion platform—which include ROCS, FastROCS, BROOD, OMEGA, OEChemTK, Grapheme, Nonequilibrium Switching (NES) Free Energy Calculations and other tools—enable computational chemists working with the ASAP Discovery Consortium to build a robust antiviral drug discovery pipeline using technology, structural biology, artificial intelligence (AI), machine learning and computational chemistry.

“Open-science drug discovery against future pandemics is an essential public service,” said Chodera. “We are thrilled to have access to OpenEye’s industry-leading software in this effort. The OpenEye Toolkits have long been the backbone of our computer-aided drug discovery infrastructure, and access to the Orion NES Free Energy workflows allows us to run free energy calculations in mere hours.”

The ASAP Discovery Consortium is an Antiviral Drug Discovery (AViDD) U19 Center for Pathogens of Pandemic Concern funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), via a $68 million grant as part of the Antiviral Program for Pandemics (APP).

The NIH grant is for the initial three-year phase of the ASAP Discovery Consortium, which aims to deliver multiple drug candidates ready for evaluation in humans in the event of an ongoing or emerging pandemic threat. The project will maximize the use of an open science model that prioritizes global, equitable and affordable access to antiviral medicine, generating a wealth of antiviral data shared rapidly and openly.

ASAP builds on the successes of the COVID Moonshot, a global, open-science collaboration that began in March 2020 and rapidly identified potent antivirals targeting the main protease of the SARS-CoV-2 virus. In July 2021, Moonshot received $11M in funding from the Wellcome Trust to pursue an accelerated preclinical program via the World Health Organization Access to COVID Tools Accelerator (ACT-A) and is working with the Drugs for Neglected Diseases Initiative (DNDi) to pursue clinical trials with a straight-to-generics model.

The ASAP Discovery Consortium is led by PIs John Chodera (MSKCC), Alpha Lee (PostEra) and Peter Sjö (DNDi). ASAP partners include the Diamond Light Source (UK), the Weizmann Institute of Science (Israel), Medchemica (UK), Mount Sinai (USA), the Stanford University School of Medicine (USA) and the Fred Hutchinson Cancer Center (USA), as well as a vast global network of scientists and industry collaborators.

About ASAP

The AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium uses artificial intelligence and computational chemistry to accelerate structure-based open-science antiviral drug discovery and deliver oral antivirals for pandemics with the goal of global, equitable and affordable access.

For more information about ASAP, including a complete list of diseases and drug targets and all open data that it has generated, visit https://asapdiscovery.org/.

About Cadence

Cadence is a pivotal leader in electronic systems design, building upon more than 30 years of computational software expertise. The company applies its underlying Intelligent System Design strategy to deliver software, hardware and IP that turn design concepts into reality. Cadence customers are the world’s most innovative companies, delivering extraordinary electronic products from chips to boards to complete systems for the most dynamic market applications, including hyperscale computing, 5G communications, automotive, mobile, aerospace, consumer, industrial and healthcare. For eight years in a row, Fortune magazine has named Cadence one of the 100 Best Companies to Work For.

Learn more at cadence.com.

XRHealth Introduces Full PTSD Package for XR Therapy

BOSTON, MA, Dec 7, 2023 – XRHealth, a leading healthcare platform in spatial computing, announces that they are releasing a full PTSD package for XR therapy. The offering will include practices in mindfulness, art therapy, cognitive behavioral therapy, exposure therapy, and EMDR. Due to the current need, XRHealth also opened a PTSD center in Tel Aviv, Israel, where clinical therapy and training in spatial computing treatment for trauma is done which will become a world hub for the use of XR to treat trauma.

The release of the PTSD package comes after the release of hostages and terrorist attacks in Israel. The PTSD package aims to assist in the recovery of those affected by the attacks in Israel by increasing daily functioning and reducing the burden from mental health clinicians. XRHealth has actively deployed VR therapy headsets throughout hospitals in Israel to aid in the recovery of the crisis. Within a few months, the PTSD package will be rolled out in the United States and Europe.

Once a patient is identified as a candidate for the PTSD package, they will receive a headset at home that is preloaded with a VR mindfulness self-guided intervention that will address symptoms of emotional dysregulation, insomnia, and stress while the patient is on the waiting list for a provider to assist with treatment. When the patient is assigned a therapist, they will begin to treat the trauma with virtual reality that will immerse the user in environments that elicit the underlying feelings of the trauma, which helps them process the trauma more quickly. They will also be treated under EMDR protocols powered by the VR headsets. Clinicians will also assign VR homework for the patient to complete between sessions and will be able to monitor progress remotely.

“We believe our technology can make a big impact on the Israeli market and help a lot of people suffering from trauma that resulted from the war. The PTSD package and our services are designed to create a virtual environment where patients could recover more quickly from trauma on site or from the comfort of their own home,” says Eran Orr, CEO of XRHealth. “We incorporated many treatment modalities that are used by therapists globally to treat trauma and the added value of virtual reality creates an immersive environment so that patients can be engaged with treatment actively while the clinician can receive data insights to monitor the users’ progress.”

About XRHealth

XRHealth is revolutionizing healthcare utilizing spatial computing. The company operates state-of-the-art therapeutic care Virtual Rooms, utilizing proprietary FDA and CE registered medical Extended Reality (XR) technology (virtual and augmented reality). XRHealth integrates immersive XR technology, licensed clinicians, and advanced data analytics on one platform, providing a comprehensive therapeutic care solution for patients to receive treatment from the comfort of their home. The company offers a variety of patent-pending solutions from rehabilitation services to cognitive assessment and training to pain management. XRHealth works with several world-renowned US healthcare providers, hospitals, and rehabilitation centers. Founded in 2016, XRHealth is headquartered in Boston, Massachusetts and its R&D center is located in Tel-Aviv, Israel.

For more information, visit www.xr.health.